AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8811376
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral intake (Group I) allowed ab libitum intake of clear liquids starting the first evening after the operation, progressing to a regular diet on the first postoperative day.
Trial: 8811376
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral intake (Group I)
Trial: 2865518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mefloquine and sulfadoxine/pyrimethamine
Trial: 29859849
Drug: D-amp 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amp 0.3 mg/kg
Trial: 27572344
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (15 sessions, daily 30 min)
Trial: 27572344
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (same amount as experimental group)
Trial: 23011680
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prednisone daily with methotrexate-based tight control strategy
Trial: 16365721
Drug: Oily calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily calcium hydroxide suspension (OCHS) with access flap surgery (AFS)
Trial: 17915977
Drug: Lamotrigine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (200 mg/day)
Trial: 11134101
Drug: OGTT+F (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT+F (75 g glucose + 7.5 g fructose)
Trial: 11134101
Drug: OGTT‐F (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT‐F (75 g glucose without fructose)
Trial: 8277075
Drug: Nitroglycerin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin plus N-acetylcysteine (0.1 microgram/kg per min + 2 g intravenously, followed by 5 mg/kg per h)
Trial: 2929629
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg PPA
Trial: 2929629
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg PPA plus 400 mg caffeine
Trial: 2929629
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg PPA
Trial: 29703040
Drug: Electro-acupuncture (EA)
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture (EA) at ST36-ST37, 20 minutes twice a day for 5 days
Trial: 29703040
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (control group)
Trial: 28396238
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose low molecular weight heparin (LMWH) combined with graduated compression stockings (GCS)
Trial: 28396238
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose low molecular weight heparin (LMWH) alone
Trial: 22033572
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (Beconase(®)), 200 μg daily
Trial: 22033572
Drug: Placebo (FESS(®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (FESS(®) saline nasal spray)
Trial: 15918622
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting octreotide (100 mcg subcutaneously thrice daily for two weeks, then 20 mg intramuscularly monthly)
Trial: 15918622
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 patients who refused treatment)
Trial: 12558577
Drug: Sulthiame (STM)
RxNorm normalized name: Sulthiame
DrugBank: Sulthiame (DB08329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulthiame (STM) monotherapy
Trial: 8383150
Drug: Bacteriostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriostatic saline solution with 1% lidocaine with epinephrine 1:300,000
Trial: 8383150
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine with epinephrine 1:100,000 with sodium bicarbonate 80 meq/mL
Trial: 8383150
Drug: Bacteriostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriostatic saline solution with 1% lidocaine with epinephrine 1:100,000
Trial: 3017392
Drug: Sodium bicarbonate,
RxNorm normalized name: Sodium Bicarbonate, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate, 2 g, administered 6 hourly for three doses daily beginning 1 day before DEC was started and continued throughout the DEC therapy.
Trial: 3017392
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bicarbonate treatment).
Trial: 29773717
Drug: PD-1 inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitors (nivolumab)
Trial: 23238355
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg racemic ibuprofen suppository
Trial: 23238355
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen syrup
Trial: 20479446
Drug: 870- and
RxNorm normalized name: choline
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 870- and 930-nm light exposure treatment
Trial: 16323028
Drug: Lipid-based nasal
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nasal ointment
Trial: 16323028
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-use of the test agent)
Trial: 8600199
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for symptomatic bacteriuria
Trial: 8600199
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment or placebo (Control)
Trial: 8358504
Drug: THA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THA treatment
Trial: 29551430
Drug: GnRHa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa plus add-back (Leuprolide depot 11.25 mg intramuscular injection every 3 months, plus oral norethindrone acetate 5 mg daily)
Trial: 29551430
Drug: GnRHa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa plus modified 2-drug add-back regimen (oral norethindrone acetate 5 mg daily and oral conjugated equine estrogens 0.625 mg daily)
Trial: 29282929
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip group (group A)
Trial: 29282929
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application group (group B)
Trial: 20875374
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR 150 mg
Trial: 18550935
Drug: Valsartan/HCTZ (160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ (160/12.5 mg)
Trial: 18550935
Drug: HCTZ (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ (25 mg)
Trial: 10748772
Drug: Pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 1 mg/kg i.v. 5 minutes before induction of anaesthesia (before skin incision)
Trial: 10748772
Drug: Pethidine administered
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine administered intraoperatively
Trial: 10748772
Drug: Postoperative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesic requirements
Trial: 8768686
Drug: Taped music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taped music and a message from their physicians during the next four chemotherapy treatments (n = 47)
Trial: 1673587
Drug: Intravenous xamoterol
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous xamoterol
Trial: 1673587
Drug: Oral xamoterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral xamoterol, 200 mg twice daily
Trial: 1673587
Drug: Oral xamoterol
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral xamoterol
Trial: 30801699
Drug: High-dose adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenocorticotropic hormone (ACTH)
Trial: 30801699
Drug: High-dose adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenocorticotropic hormone (ACTH) without prior vigabatrin (VGB)
Trial: 30801699
Drug: High-dose adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenocorticotropic hormone (ACTH) with prior vigabatrin (VGB)
Trial: 27364900
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg IR/ER every 12 hours
Trial: 27364900
Drug: Standard ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ibuprofen 200 mg IR every 4 hours
Trial: 27364900
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg IR/ER with food
Trial: 27364900
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ibuprofen IR/ER
Trial: 21289620
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral synthetic THC
Trial: 21289620
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oral synthetic THC
Trial: 3240842
Drug: 10% protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% protein diet (0.9 +/- 0.06 g.kg‐1.day‐1)
Trial: 3240842
Drug: 20% protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% protein diet (1.9 +/- 0.1 g.kg‐1.day‐1)
Trial: 29330997
Drug: Various Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various Vitamin D3 preparations (Cholecalciferol) administered orally and intramuscularly
Trial: 17023868
Drug: Methylphenidate at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate at titrated doses (average, 14.2 mg/day) administered three times daily, 7 days/week for approximately 1 year
Trial: 17023868
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment for 95 children who remained on medication
Trial: 3929320
Drug: Chronic lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic lithium treatment
Trial: 3929320
Drug: Other psychoactive
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other psychoactive drugs (not specified)
Trial: 22978101
Drug: CM +
RxNorm normalized name: Trametes versicolor strain CM-101 extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM + chemotherapy
Trial: 10233188
Drug: OAM =
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OAM = omeprazole 20 mg b.d. + amoxycillin 1 g b.d. + metronidazole 500 mg b.d.
Trial: 10233188
Drug: RAM =
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RAM = ranitidine 300 mg b.d. + amoxycillin 1 g b.d. + metronidazole 500 mg b.d.
Trial: 10233188
Drug: OAC =
RxNorm normalized name: Oral Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC = omeprazole 20 mg b.d. + amoxycillin 1 g b.d. + clarithromycin 250 mg t.d.s.
Trial: 10233188
Drug: RAC =
RxNorm normalized name: Ractopamine
DrugBank: Ractopamine (DB11541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC = ranitidine 300 mg b.d. + amoxycillin 1 g b.d. + clarithromycin 250 mg t.d.s.
Trial: 8904327
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g EACA upon initiation of cardiopulmonary bypass (CPB)
Trial: 8904327
Drug: No antifibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antifibrinolytic drugs prior to CPB
Trial: 27002280
Drug: PA32540 (enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg)
Trial: 27002280
Drug: EC-ASA (enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-ASA (enteric-coated aspirin 325 mg)
Trial: 24385131
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low doses of ethanol (<5 mM blood concentration)
Trial: 22179861
Drug: Oxycodone (Opioid)
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone (Opioid)
Trial: 14693590
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg 2% preservative-free 2-chloroprocaine
Trial: 14693590
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg 2% lidocaine
Trial: 12378742
Drug: Atovaquone +
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone + proguanil combination
Trial: 2547950
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 to 100 mg daily)
Trial: 327854
Drug: Hydroxyzine HCl
RxNorm normalized name: hydroxyzine HCl
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine HCl (50 mg)
Trial: 31788318
Drug: Dotinurad (0.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotinurad (0.5-20 mg single-dose administration)
Trial: 26480553
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding therapy applied to Qugu (CV 2), Shenshu (BL 23), Zhibian (BL 54), Huiyin (CV 1) and Sanyinjiao (SP 6), once every two weeks for 4 weeks, with two sessions total.
Trial: 26480553
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group: tamsulosin capsules 0.2 mg once daily and indometacin sustained release tablets 25 mg three times daily for 8 weeks.
Trial: 15279041
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with first generation agents
Trial: 8305125
Drug: CRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH plus TRH administration
Trial: 3423736
Drug: Cigarette smoking
RxNorm normalized name: Cigarette smoking tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoking after cimetidine pretreatment (2 X 400 mg orally for 2 days and 400 mg orally 1.5 h before examination)
Trial: 30986958
Drug: Pistachios (56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachios (56 g, 1318 kJ)
Trial: 30986958
Drug: Savory biscuits
RxNorm normalized name: winter savory oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savory biscuits (56 g, isoenergetic/equiprotein)
Trial: 28196772
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Group therapy (ACT‐G)
Trial: 21592186
Drug: Cryotherapy gel
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy gel wrap applied to lower leg skin for 30 minutes daily for four weeks
Trial: 18269390
Drug: Starch solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch solutions
Trial: 17278430
Drug: Chemotherapy (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (one course) for group B patients
Trial: 17278430
Drug: Total chemotherapy
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total chemotherapy for group B patients
Trial: 8491007
Drug: Coumadin (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumadin (with heparin until oral anticoagulation established)
Trial: 8491007
Drug: Placebo (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with discontinuation of heparin)
Trial: 30217640
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of vasoactive medication use (in days)
Trial: 30217640
Drug: Cumulative norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative norepinephrine dose (μg/kg/d)
Trial: 26888712
Drug: DIET (25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIET (25% daily needs energy deficits induced by diet only)
Trial: 26888712
Drug: EX (25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX (25% daily needs energy deficits induced by exercise only)
Trial: 22081005
Drug: Losartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan + Simvastatin (20 mg/day)
Trial: 22081005
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Simvastatin (20 mg/day)
Trial: 20171410
Drug: Carbomer-based lipid-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbomer-based lipid-containing gel (CBLC)
Trial: 20171410
Drug: HP-guar gel
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-guar gel
Trial: 18165396
Drug: Raloxifene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (180 mg daily)
Trial: 11576046
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% plus hyaluronidase 100 i.u. ml‐1
Trial: 11576046
Drug: mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixture of lidocaine 2% and bupivacaine 0.5% (2:3 volume per volume) containing hyaluronidase 25 i.u. ml‐1
Trial: 8140940
Drug: NaF at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF at 75 mg/day
Trial: 3395500
Drug: Weekly prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly prescription for BSE
Trial: 3395500
Drug: Every-two-weeks prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every-two-weeks prescription for BSE
Trial: 3395500
Drug: Monthly prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly prescription for BSE
Trial: 28626213
Drug: Imrecoxib 200
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Imrecoxib 200 mg twice daily
Trial: 16575010
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m2 IV daily for 5 days every 4 weeks)
Trial: 16575010
Drug: CVP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVP (cyclophosphamide 750 mg/m2 IV on day 1; vincristine 1.4 mg/m2 IV on day 1; prednisone 40 mg/m2 orally on days 1-5 every 4 weeks)
Trial: 10690763
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI, 1 sperm injected)
Trial: 9139174
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of hot red pepper
Trial: 29735470
Drug: Oral ulcer
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral ulcer powder combined with Kangfuxin liquid
Trial: 22759259
Drug: Calcium hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxylapatite (CaHA) injections
Trial: 12595874
Drug: Transcranial electrostimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial electrostimulation treatment (TCET)
Trial: 11013193
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 0.1% (20 patients)
Trial: 8628597
Drug: Lovastatin 10
RxNorm normalized name: lovastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 10 mg/d
Trial: 8628597
Drug: Lovastatin 30
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin 30 mg/d
Trial: 1484946
Drug: Ice/slush topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice/slush topical hypothermia (Group I)
Trial: 1484946
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical hypothermia (Group II)
Trial: 3883733
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of molsidomine three times daily
Trial: 3883733
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of molsidomine six times daily
Trial: 3883733
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of molsidomine
Trial: 3883733
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of sustained-release molsidomine
Trial: 3883733
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of molsidomine four times daily